Forte Biosciences

Forte Biosciences is a clinical-stage biopharmaceutical company developing immunotherapies for autoimmune and immunology-related diseases. The company's lead candidate FB102 is an IL-2/IL-15 pathway antagonist under investigation for vitiligo and other autoimmune indications; the FB102 double-blind placebo-controlled Phase 1b study in vitiligo announced July 9, 2026 showed 29.6% mean Face Vitiligo Area Scoring Index (FVASI) improvement at week 24 (p=0.020) and a 43.2% mean FVASI improvement in patients with greater baseline disease involvement (p=0.006). Forte is headquartered in Dallas, Texas and trades on the Nasdaq Capital Market under the symbol FBRX.